Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

@article{Dupuis2015CombinationOR,
  title={Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.},
  author={Jehan M Dupuis and Franck Morschhauser and Herv{\'e} Ghesqui{\`e}res and Herv{\'e} Tilly and Olivier Casasnovas and Catherine Thi{\'e}blemont and Vincent Ribrag and C{\'e}line J Bossard and Fabien Le Bras and Emmanuel Bachy and B{\'e}n{\'e}dicte Hivert and Emmanuelle Nicolas-Virelizier and Fabrice Jardin and Jean-No{\"e}l Bastie and Sandy Amorim and Julien Lazarovici and Antoine Martin and Bertrand Coiffier},
  journal={The Lancet. Haematology},
  year={2015},
  volume={2 4},
  pages={
          e160-5
        }
}
BACKGROUND Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin combined… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Similar Papers

Loading similar papers…